文献速递神经肿瘤

脑膜瘤中的致病性变异与预后:一项系统综述与Meta分析

Pathogenic Variants and Prognosis in Meningiomas: A Systematic Review and Meta-Analysis.
PubMed 文献 · World Neurosurg · 2025-04-19

该系统综述与Meta分析纳入20项研究,评估脑膜瘤基因变异与复发或生存的预后关联。TERTp和NF2变异分别与更短的无复发生存期和总生存期相关,TERTp的无复发生存期风险比4.35、总生存期风险比2.55,NF2的无复发生存期风险比1.49、总生存期风险比2.98。

要点

  • TERTp变异与更短无复发生存期(HR 4.35)和总生存期(HR 2.55)相关。
  • NF2变异与更短无复发生存期(HR 1.49)和总生存期(HR 2.98)相关。
  • KLF4为保护因素,CDKN2A/B为风险因素。

核心结论

  • TERTp和NF2等致病性变异是颅内脑膜瘤的预后标志物,将基因分型整合入临床实践可能有助于细化风险分层并指导个体化治疗策略,最终改善患者结局与生活质量。

研究设计与样本

  • 遵循PRISMA指南的系统综述与Meta分析,检索PubMed、EMBASE、Web of Science和Scopus截至2024年11月的文献,纳入报告基因变异与预后(复发或生存)数据且样本量至少5例的研究,由两名评价者独立提取和分析数据。
  • 共识别3032项研究,其中20项符合纳入标准。

主要发现

  • 研究最多的致病性变异为端粒酶逆转录酶启动子(TERTp)和神经纤维瘤病2型(NF2),二者分别与更短的无复发生存期(RFS)和总生存期(OS)相关:TERTp的RFS HR 4.35(95%CI 2.87-6.60)、OS HR 2.55(95%CI 1.25-5.22);NF2的RFS HR 1.49(95%CI 1.04-2.14)、OS HR 2.98(95%CI 1.37-6.49)。
  • 亚组分析提示TERTp变异对全部脑膜瘤(而非仅WHO III级)的低生存预测性可能更强,NF2变异情况类似。
  • Krüppel样因子4被鉴定为保护因素,细胞周期蛋白依赖性激酶抑制剂2A/B被鉴定为风险因素。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Intracranial meningiomas are the most common primary tumors of the central nervous system. Although generally benign, some genetic alterations can induce aggressive behavior characterized by higher recurrence rates and reduced survival. METHODS: A systematic review and meta-analysis were conducted following Preferred Reporting Items for Systematic reviews and Meta-Analyses guidelines, using PubMed, EMBASE, Web of Science, and Scopus databases to identify studies published until November 2024. Studies investigating genetic alterations in meningiomas with prognostic data (recurrence or survival) and a minimum sample size of five patients were included. Data were extracted and analyzed independently by two reviewers. RESULTS: Of 3032 studies identified, 20 met the inclusion criteria. The most frequently studied pathogenic variants were telomerase reverse transcriptase promoter (TERTp) and neurofibromatosis type 2 (NF2), both associated with shorter recurrence-free survival (RFS) and overall survival (OS), respectively TERTp RFS (hazard ratio [HR] 4.35, 95% confidence interval [CI] 2.87-6.60) and OS (HR 2.55, 95%CI 1.25-5.22), and NF2 RFS (HR 1.49, 95%CI 1.04-2.14) and OS (HR 2.98, 95% CI 1.37-6.49). Subgroup analysis suggested that the TERTp variant may be more predictive of lower survival for overall meningiomas (instead of World Health Organization III only), similar to NF2 variants. Additionally, Krüppel-like factor 4 was identified as a protective factor, while cyclin-dependent kinase inhibitor 2A/B was identified as a risk factor. CONCLUSIONS: This systematic review highlights the importance of pathogenic variants, particularly TERTp and NF2, as prognostic markers in intracranial meningiomas. These findings underscore the potential of integrating genetic profiling into clinical practice to refine risk stratification and guide personalized therapeutic strategies, ultimately improving patient outcomes and quality of life.

来源:World Neurosurg,查看原文。版权归原作者所有。

引用

  1. Zuniga RDDR, Carrijo GS, do Vale MR, et al. Pathogenic Variants and Prognosis in Meningiomas: A Systematic Review and Meta-Analysis. World Neurosurg. 2025. PMID: 40254182. doi:10.1016/j.wneu.2025.123988

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。